New drug cocktail aims to shrink lung tumors

NCT ID NCT07241767

Recruiting now Disease control Sponsor: Jiangsu HengRui Medicine Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests an experimental drug called FH-006 combined with other cancer treatments in 200 people with advanced non-small cell lung cancer. The goal is to see if the combination is safe and can shrink tumors. Researchers will also determine the best dose for future studies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: FH-006 (an experimental drug) combined with other anti-tumor therapies
What this could lead to: If successful, this could point toward a new combination treatment for advanced lung cancer.
What could go wrong: This is an early phase 2 trial, so the drug may not work or could cause side effects. Results may not apply to all lung cancer patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung cancer lung neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUNG CANCER

Contacts and locations

Locations

Sun Yat-sen University Cancer Center
RECRUITING

Guangzhou, Guangdong, 510060, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.